资讯

PharmiWeb10 小时

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

On Track To Be First Mover In $7Bn Addressable Market With No Current Therapeutic OptionsBy: Benzinga Staff Writer CARDIFF, ...